CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Bioabsorbable Everolimus Eluting Coronary Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00300131
NCT00300131N/ACompleted
CompareCT.gov

Bioabsorbable Vascular Solutions First in Man Clinical Investigation: A Clinical Evaluation of the Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With Single de Novo Native Coronary Artery Lesions

Abbott Medical Devices·observational·Posted Mar 8, 2006·Updated Sep 13, 2011

In Brief

An observational study evaluating Bioabsorbable Everolimus Eluting Coronary Stent for Coronary Disease and 2 related conditions. Completed, enrolled 30 participants across 4 sites in 4 countries.

Detailed Summary

Prospective, open-labeled First in Man Clinical Investigation enrolling patients with visually estimated nominal vessel diameter of 3.0 mm receiving a single 3.0 x 12 mm or 3.0 x 18 mm BVS EECSS containing 98 microgramme per cm² of surface area.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease, Coronary Artery Disease, Coronary Restenosis
CountriesDenmark, Netherlands, New Zealand, Poland
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 8, 2006
Enrollment StartMar 1, 2006
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 20.3 years ago

Interventions

Bioabsorbable Everolimus Eluting Coronary Stentdevice

Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease